

Journal Pre-proof

Erratum to: Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement



PII: S2667-1743(22)00140-9

DOI: <https://doi.org/10.1016/j.bpsgos.2022.11.001>

Reference: BPSGOS 184

To appear in: *Biological Psychiatry Global Open Science*

Received Date: 1 November 2022

Please cite this article as: Erratum to: Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement, *Biological Psychiatry Global Open Science* (2022), doi: <https://doi.org/10.1016/j.bpsgos.2022.11.001>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 THE AUTHORS. Published by Elsevier Inc. on behalf of Society of Biological Psychiatry.

Erratum to: “Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement”, by Lee *et al.* (*Biol Psychiatry Glob Open Sci* 2022; 2:127-135); <https://doi.org/10.1016/j.bpsgos.2021.09.003>.

The authors have realized that the enrollment dates for the trial are incorrect. Currently, the Methods section states that participants were recruited from July 2009 to July 2014, but recruitment actually occurred from February 2015 to November 2017.

Journal Pre-proof